What is a stock summary page? Click here for an overview.
Business Description
Waverley Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA94357L1058
Description
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | -1.13 | |||||
Debt-to-Equity | -1.47 | |||||
Debt-to-EBITDA | -1.63 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -16.56 | |||||
Beneish M-Score | -8.2 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.6 | |||||
3-Year EBITDA Growth Rate | -4.9 | |||||
3-Year EPS without NRI Growth Rate | -32 | |||||
3-Year FCF Growth Rate | -39.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.62 | |||||
9-Day RSI | 40.57 | |||||
14-Day RSI | 43.57 | |||||
6-1 Month Momentum % | -60 | |||||
12-1 Month Momentum % | -71.43 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.13 | |||||
Quick Ratio | 0.09 | |||||
Cash Ratio | 0.07 | |||||
Days Inventory | 117.58 | |||||
Days Sales Outstanding | 116.2 | |||||
Days Payable | 818.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -224.85 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 20.71 | |||||
Operating Margin % | -573.37 | |||||
Net Margin % | -905.33 | |||||
FCF Margin % | -310.36 | |||||
ROA % | -217.95 | |||||
ROIC % | -68.66 | |||||
3-Year ROIIC % | -160.24 | |||||
ROC (Joel Greenblatt) % | -766.54 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.67 | |||||
EV-to-EBIT | -1.67 | |||||
EV-to-EBITDA | -1.8 | |||||
EV-to-Revenue | 9.65 | |||||
EV-to-FCF | -3.11 | |||||
Price-to-GF-Value | 0.33 | |||||
Earnings Yield (Greenblatt) % | -59.88 | |||||
FCF Yield % | -194.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Waverley Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 0.338 | ||
EPS (TTM) (C$) | -0.055 | ||
Beta | 1.89 | ||
3-Year Sharpe Ratio | 0.1 | ||
3-Year Sortino Ratio | 0.17 | ||
Volatility % | 116.06 | ||
14-Day RSI | 43.57 | ||
14-Day ATR (C$) | 0.000919 | ||
20-Day SMA (C$) | 0.0115 | ||
12-1 Month Momentum % | -71.43 | ||
52-Week Range (C$) | 0.01 - 0.035 | ||
Shares Outstanding (Mil) | 54 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Waverley Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Waverley Pharma Inc Stock Events
Event | Date | Price (C$) | ||
---|---|---|---|---|
No Event Data |
Waverley Pharma Inc Frequently Asked Questions
What is Waverley Pharma Inc(TSXV:WAVE)'s stock price today?
The current price of TSXV:WAVE is C$0.01. The 52 week high of TSXV:WAVE is C$0.04 and 52 week low is C$0.01.
When is next earnings date of Waverley Pharma Inc(TSXV:WAVE)?
The next earnings date of Waverley Pharma Inc(TSXV:WAVE) is .
Does Waverley Pharma Inc(TSXV:WAVE) pay dividends? If so, how much?
Waverley Pharma Inc(TSXV:WAVE) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |